Reply to correspondence: Gastrointestinal determinants of levodopa response in Parkinson's disease: An integrated perspective.
文献摘要
levodopa pharmacokinetic variability in Parkinson's disease, and we agree that gastrointestinal determinants of treatment response extend beyond gastric emptying. However, our review was deliberately focused on gastroparesis, while explicitly acknowledging that levodopa is absorbed in the duodenum and proximal jejunum and that gastrointestinal dysfunction in Parkinson's disease may involve more generalized transit abnormalities, small intestinal bacterial overgrowth, and gut microbiota-related mechanisms. Importantly, prolonged small bowel transit alone does not establish the direction or magnitude of its effect on levodopa bioavailability, nor does current evidence demonstrate that intestinal dysmotility is a more direct or predominant determinant than delayed gastric emptying. Rather than opposing gastric and intestinal mechanisms, we propose that gastric emptying, small bowel motility, and other pharmacokinetic, pharmacodynamic, and disease-related factors should be viewed as sequential, interdependent, and patient-specific determinants of levodopa response. Integrated studies combining gastrointestinal transit assessment, levodopa pharmacokinetics, and motor outcomes are therefore warranted.